ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0545

The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series

Naomi Serling-Boyd1, Amir Mohareb2, Arthur Kim2, Emily Hyle2 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Newton, MA

Meeting: ACR Convergence 2020

Keywords: COVID-19, Infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The use of immunosuppressive medications in patients with a history of hepatitis B virus (HBV) infection is associated with an increased risk of HBV reactivation which can lead to liver failure and death. Rates of HBV reactivation have been reported in up to 24% of people with resolved HBV (positive core antibody [HBcAb], negative surface antigen [HBsAg], and positive or negative surface antibody [HBsAb]) and 34% of people with chronic HBV (positive HBsAg) in patients who are treated with tumor necrosis factor inhibitors, rituximab, and other biologics. Outside of Asia, there are limited data regarding the risk of reactivation in patients taking tocilizumab or tofacitinib, both of which have emerged as potential treatments for the systemic inflammatory manifestations of coronavirus disease 2019.

Methods: In this retrospective study, we identified patients in the Mass General Brigham (MGB) healthcare system who had ≥ 1 prescription for either tocilizumab or tofacitinib and resolved or chronic HBV between 1995 and 2018. Details regarding demographics, medical history, and laboratory results were extracted from the electronic health record. HBV reactivation was defined as a greater than 10-fold increase in HBV deoxyribonucleic acid (DNA) levels from baseline, an absolute increase > 105 copies/mL, or a positive HBsAg when previously negative.

Results: Twenty patients, all with resolved HBV, were included (Table 1). Four patients received tofacitinib and tocilizumab sequentially such that there were 24 medication exposures. The median age at treatment initiation was 59 years (tofacitinib) and 66 years (tocilizumab) and the majority were female. The majority of patients treated with tocilizumab (16, 100%) and tofacitinib (7, 88%) were HBsAb positive at baseline. Concurrent immunosuppression was used in 12 (75%) tocilizumab-treated patients and 6 (75%) tofacitinib-treated patients. Anti-viral treatment was prescribed in 25% of cases in both groups. Median follow-up time after treatment initiation was 4.0 years in the tocilizumab group and 3.1 years in the tofacitinib group. During follow-up, all patients had aminotransferases measured at least once, and no patients had transaminitis attributed to HBV reactivation. Among the patients who had ≥ 1 HBV polymerase chain reaction or HBsAg assessed after treatment initiation (13 [81%] in the tocilizumab group and 4 [50%] in the tofacitinib group), none were positive.

Conclusion: We found no instances of HBV reactivation in patients with resolved HBV exposed to tocilizumab or tofacitinib. A quarter of people in our study were prescribed antivirals and many had no follow up serologic studies to evaluate for reactivation, reflecting the uncertainty regarding best practices for patients with resolved HBV. Our findings suggest that tocilizumab or tofacitinib may be safely used in patients with resolved HBV infection.

Table 1. Demographics, clinical characteristics, and follow up of study population


Disclosure: N. Serling-Boyd, None; A. Mohareb, None; A. Kim, Biomarin, Inc, 7; E. Hyle, None; Z. Wallace, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Serling-Boyd N, Mohareb A, Kim A, Hyle E, Wallace Z. The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-use-of-tocilizumab-and-tofacitinib-in-patients-with-resolved-hepatitis-b-infection-a-case-series/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-use-of-tocilizumab-and-tofacitinib-in-patients-with-resolved-hepatitis-b-infection-a-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology